Physician profile
Benjamin Folk
NPI 1629010012
$3,075.58
in general payments reported to CMS, 2019-2025
22 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $547 · 2021: $593 · 2022: $391 · 2023: $505 · 2024: $280 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,038.19 | 2019-2025 | Leqvio |
| Astrazeneca Pharmaceuticals Lp | $372.30 | 2020-2024 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $222.58 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.02 | 2021-2022 | |
| Amgen INC. | $158.57 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $150.00 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $126.59 | 2022-2023 | Optimizer |
| Pfizer INC. | $121.10 | 2019-2025 | |
| Scpharmaceuticals INC. | $112.90 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $100.33 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $80.92 | 2023-2024 | Accolade Sr, Watchman, Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $73.06 | 2021-2023 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Sanofi-Aventis U.S. LLC | $69.51 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.24 | 2025 | |
| Bridgebio Pharma, INC. | $56.81 | 2025 | Attruby |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $38.11 | 2024 | |
| Alnylam Pharmaceuticals INC. | $28.30 | 2025 | Amvuttra |
| United Therapeutics Corporation | $20.20 | 2024 | Tyvaso |
| Astellas Pharma US INC | $17.12 | 2019 | |
| Glaxosmithkline, LLC. | $13.73 | 2025 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $12.88 | 2019 | |
| Sanofi Pasteur INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Folk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.